Literature DB >> 10886396

Efficient induction of an antigen-specific, T helper type 1 immune response by interleukin-12-secreting fibroblasts.

T S Kim1, K M Kim, B A Shin, S Y Hwang.   

Abstract

To determine whether the paracrine secretion of interleukin (IL)-12 can efficiently convert immune responses characterized by high levels of synthesis of IL-4 and immunoglobulin E (IgE) into T helper 1 (Th1)-dominated responses, 3T3 fibroblasts were stably transfected to secrete IL-12 (480 units/10(6) cells/48 hr). Their effects on the T helper cell-mediated immune response were investigated in ovalbumin (OVA)-primed mice. Free mouse recombinant IL-12 was included as a control group. IL-12-secreting fibroblasts (3T3/IL-12) were more effective than free recombinant IL-12 at increasing OVA-specific interferon-gamma (IFN-gamma) production and decreasing OVA-specific IL-4 production in CD4+ T cells. In addition, injection with 3T3/IL-12 cells significantly increased anti-OVA immunoglobulin G2a (IgG2a) levels and decreased anti-OVA IgE levels in OVA-primed mice. This work suggests that IL-12-secreting fibroblasts can efficiently induce an antigen-specific Th1 response and may be beneficial in the treatment of diseases caused by undesirable T helper 2 (Th2)-dominated responses, including allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886396      PMCID: PMC2327009          DOI: 10.1046/j.1365-2567.2000.00038.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  31 in total

Review 1.  Cytokine secretion phenotypes of TH cells: how many subsets, how much regulation?

Authors:  T R Mosmann
Journal:  Res Immunol       Date:  1991-01

Review 2.  The role of helper T cell subsets in autoimmune diseases.

Authors:  J J Lafaille
Journal:  Cytokine Growth Factor Rev       Date:  1998-06       Impact factor: 7.638

Review 3.  Th1/Th2 balance in human disease.

Authors:  M D'Elios; G Del Prete
Journal:  Transplant Proc       Date:  1998-08       Impact factor: 1.066

4.  The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

Authors:  L C Afonso; T M Scharton; L Q Vieira; M Wysocka; G Trinchieri; P Scott
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

5.  Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study.

Authors:  R E Sobol; D L Shawler; C Carson; C Van Beveren; D Mercola; H Fakhrai; M A Garrett; R Barone; P Goldfarb; R M Bartholomew; S Brostoff; D J Carlo; I Royston; D P Gold
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

6.  Interleukin-12-secreting fibroblasts are more efficient than free recombinant interleukin-12 in inducing the persistent resistance to Mycobacterium avium complex infection.

Authors:  B Y Kang; S W Chung; Y S Lim; E J Kim; S H Kim; S Y Hwang; T S Kim
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

7.  Adjuvant immunotherapy using fibroblasts genetically engineered to secrete interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model.

Authors:  G Matsumoto; M Sunamura; H Shimamura; T Kodama; W Hashimoto; M Kobari; K Kato; K Takeda; H Yagita; K Okumura; H Hamada; S Matsuno
Journal:  Surgery       Date:  1999-03       Impact factor: 3.982

8.  Allergen-dependent induction of interleukin-4 synthesis in vivo.

Authors:  X Yang; K T Hayglass
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

9.  Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses.

Authors:  J L Grun; P H Maurer
Journal:  Cell Immunol       Date:  1989-06       Impact factor: 4.868

10.  Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.

Authors:  H Tahara; H J Zeh; W J Storkus; I Pappo; S C Watkins; U Gubler; S F Wolf; P D Robbins; M T Lotze
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

View more
  1 in total

Review 1.  Enhancing cellular cancer vaccines.

Authors:  Edward P Cohen; Amla Chopra; InSug O-Sullivan; Tae Sung Kim
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.